Verification of delivered dose to the Lips carcinoma tumors with HDR brachytherapy sources: 192Ir and 60CO in an exclusive plexiglass Phantom.

Document Type : Conference Proceedings


1 MSc student of Medical physic, Kermanshah university of medical science, Kermanshah, Iran

2 Mahdieh Radiotherapy and brachytherapy charity center, Hamedan. Iran

3 Mahdieh Radiotherapy and Oncology charity Centre, Hamadan. Iran Islamic Azad University, Science and research branch, Tehran, Iran

4 Tehran University of Medical Sciences · Department of Radiation Oncology, Tehran, Iran


Introduction: Brachytherapy, especially using manually after loaded Iridium-192 and Cobalt-60, can be applied as a sole treatment, as a treatment complementary to surgery, and as a local boost in combination with EBRT. The use of HDR brachytherapy catheters incorporated in removable dental molds allows repeated, highly reproducible, fractionated outpatient brachytherapy of superficial tumors without requiring repeated catheter insertion into the tumor. One of the important use of molds is controlling hyper dose sleeves. Some suitable sites for mould therapy include the scalp, lip, buccal mucosa and hard palate. In this study, we are going to dosimetry this lips mould with TLD-100 and comparing with Plexiglass exclusive phantom results.
Materials and Methods: This study has done for an early stage lip squamous cell carcinoma with mold and an exclusive lips phantom that were definitively done with using HDR brachytherapy. A customized mold was fabricated for a patient with lips superficial tumor and TLD-100 were located in the surface of mold and phantom, in which 3-4 after loading catheters were placed for passing the Iridium and Cobalt sources.
Results: The results show that we have difference about 2 percent between dose calculation for mold and phantom for Iridium and about 1.5 percent for Cobalt.
Conclusion: HDR brachytherapy using the mold technique as definitive treatment or for boosting the dose after radiotherapy, is a safe and excellent method for selected early and superficial lip cancers.